2022 was an incredibly productive year for American scientists. Biopharmaceutical researchers conducted over 7,000 clinical programs, including more than 3,000 for cancer, 182 for cardiovascular diseases, 111 for Alzheimer’s, and 57 for Type II diabetes. Importantly, 77% of these therapeutics originated at small biotech companies working toward their first breakthrough.
{iframe}https://www.realclearpolicy.com/articles/2023/02/07/policy_changes_could_cut_short_a_golden_age_of_drug_development_880200.html{/iframe}